Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
9 pending office actions • 7 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Nanjing Genscript Biotech Co. Ltd. has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 10 distinct examiners and 7 distinct art units. This indicates broad examiner distribution across a smaller set of technical examination units, with some art units supporting more than one pending matter.
KENNEDY, SARAH JANE is the busiest examiner, with 1 pending matter. The data does not show concentration with one examiner, so portfolio management should emphasize cross-matter coordination by art unit and technology while preserving matter-specific response positions. A consolidated issue matrix may help identify recurring objections without assuming that the examiners will apply them identically.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (33%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 5 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORTOLI, JONATHAN | 1 | 76.4% | +40.2% |
| HANEY, AMANDA MARIE | 1 | 36.5% | +45.0% |
| WASHINGTON, BRITNEY NICOLE | 1 | 84.0% | +13.2% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
| PRIEST, AARON A | 1 | 61.4% | +25.6% |
| FLINDERS, JEREMY C | 1 | 63.5% | +17.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18396656 | AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR | WASHINGTON, BRITNEY NICOLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713145 | AUXILIARY CONNECTION DEVICE | BORTOLI, JONATHAN | — |
| 18293339 | PRIMER SET AND GENE CHIP METHOD FOR DETECTING SINGLE BASE MUTATION | HANEY, AMANDA MARIE | — |
| 18281849 | ANTIBODY FUSION PROTEINS AND USES THEREOF | LU, CHENG | — |
| 18279811 | DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM | CHONG, KIMBERLY | — |
| 18262420 | METHOD FOR PRODUCING TARGET DNA SEQUENCE AND CLONING VECTOR | LEITH, NANCY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758048 | Method For Constructing Gene Mutation Library | FLINDERS, JEREMY C | 8d |
| 18713145 | AUXILIARY CONNECTION DEVICE | BORTOLI, JONATHAN | — |
| 18293339 | PRIMER SET AND GENE CHIP METHOD FOR DETECTING SINGLE BASE MUTATION | HANEY, AMANDA MARIE | — |
| 18396656 | AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR | WASHINGTON, BRITNEY NICOLE | — |
| 18286880 | PLASMID SYSTEM WITHOUT SELECTABLE MARKERS AND PRODUCTION METHOD THEREOF | PERSONS, JENNA L | — |
| 18281849 | ANTIBODY FUSION PROTEINS AND USES THEREOF | LU, CHENG | — |
| 18279811 | DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM | CHONG, KIMBERLY | — |
| 18262420 | METHOD FOR PRODUCING TARGET DNA SEQUENCE AND CLONING VECTOR | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1797 | 2 |
| 1636 | 2 |
| 1682 | 1 |
| 1637 | 1 |
| 1642 | 1 |
| 1681 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713145 | AUXILIARY CONNECTION DEVICE | BORTOLI, JONATHAN | 1797 | §102§103§112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18293339 | PRIMER SET AND GENE CHIP METHOD FOR DETECTING SINGLE BASE MUTATION | HANEY, AMANDA MARIE | 1682 | §102§103§112Other | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18396656 | AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR | WASHINGTON, BRITNEY NICOLE | 1797 | §103 | Final Rejection | — | Pending | Dec 26, 2023 |
| 18286880 | PLASMID SYSTEM WITHOUT SELECTABLE MARKERS AND PRODUCTION METHOD THEREOF | PERSONS, JENNA L | 1637 | §102§103§112DPOther | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18281849 | ANTIBODY FUSION PROTEINS AND USES THEREOF | LU, CHENG | 1642 | §103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18279811 | DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18262420 | METHOD FOR PRODUCING TARGET DNA SEQUENCE AND CLONING VECTOR | LEITH, NANCY J | 1636 | §103§112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18006592 | SURFACE LINKER OF SEMICONDUCTOR CHIP, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PRIEST, AARON A | 1681 | §103 | Final Rejection | — | Pending | Jan 24, 2023 |
| 17758048 | Method For Constructing Gene Mutation Library | FLINDERS, JEREMY C | 1684 | §103 | Non-Final OA | 8d | Pending | Jun 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Genscript Biotech Co. Ltd. has 9 pending office actions as of October 2026, spread across 7 art units and 9 examiners.
Jonathan Bortoli has the most, with 1 of Nanjing Genscript Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
